Introduction
The original European Survey on Anaemia Management (ESAM 1998) [1] was conducted in parallel with the development of the European Best Practice Guidelines (EBPG) [2] . It was a 6 month follow-up observational survey which revealed that, in general, anaemia management was far from optimal. The current survey, ESAM 2003, was a retrospective, 1 day survey intended to determine whether anaemia management had improved since the publication of the EBPG 4 years earlier. Here we report the findings of ESAM 2003 on the current status of anaemia management, the key factors that influence the dose of epoetin therapy, and the resulting haemoglobin concentrations. Eight European countries participated in both surveys, and this allowed an assessment of how anaemia management in dialysis patients has changed over the last 4 years. Although the sampling fractions and randomization processes varied both between surveys and between countries, limited comparisons within individual countries are valid. More detailed comparisons were possible for Germany, which contributed 48% of the patients from the eight countries in ESAM 1998 and 60% in ESAM 2003.
Patients and methods

Study design
ESAM 2003 was designed as a retrospective, 1 day survey of adult patients with end-stage renal disease in 11
European countries and Israel. The European countries participating were Austria, Belgium, Finland, Germany, Greece, The Netherlands, Poland, Slovenia, Sweden, Switzerland and the UK. Data were collected on patients undergoing haemodialysis, haemodiafiltration or haemofiltration on an agreed date and on peritoneal dialysis patients attending a routine visit. The survey was designed to collect data readily available in the dialysis unit without the need to access historical notes, and focused on both individual patient data and the centres' anaemia management policies.
The main objective of the randomization process was to ensure that, within each country, the selected sample was representative of the dialysis population as a whole. The actual randomization process varied in each country according to the number of centres in the country. Sample fractions also varied according to the size of the country in order to achieve reasonable 95% confidence limits (CIs) for the percentage of patients with a haemoglobin level 11.0 g/dl. The maximum 95% confidence limits in a sample size of 4000 would be approximately ±1.6% but, for a sample size of only 200, they would be approximately ±7.1%. Therefore, a 1 in 16 sample of all dialysis patients was taken in the larger participating countries (1 in 4 centres and 1 in 4 patients within each centre or 1 in 8 centres and 1 in 2 patients within each centre), and a 1 in 8 sample was taken in the smaller countries (1 in 4 centres and 1 in 2 patients within each centre). Random sampling was carried out in two stages, first by centre within each participating country, and secondly, by patient within each selected centre. In most countries, the 1 in 4 sample of centres was achieved by drawing up a complete list of all dialysis centres in the country and assigning a random number to each. The centres were then sorted by random number, and the first 25% of the list were included in the survey. Any centre that refused or was unable to participate was replaced by the next available centre in the remainder of the list. In Slovenia, all three units in the sole university centre were included with a pro rata decrease in sample size (1 in 8) within that centre, and all other units were included (1 in 4 patients in each). In Germany (1094 centres), 1 in 8 centres and 1 in 2 patients within each centre were sampled. In Israel, 1 in 3 centres and 1 in 4 patients within each centre were sampled.
For random patient sampling, each participating centre drew up an alphabetical list of all haemodialysis, haemodiafiltration and haemofiltration patients aged 18 years and selected every fourth patient on the list. This should have randomly sampled the entire current centre population, independently of the frequency of dialysis or whether patients were working/not working or undergoing morning/afternoon/evening treatment. In those countries in which informed consent was required (the majority), a list of patients was drawn up on a fixed date (the list date) and informed consent sought at the next dialysis. The survey form was completed with respect to the last dialysis. In the event that informed consent was not obtained, the next available patient on the list was included.
Each centre also drew up a list of all current peritoneal dialysis patients aged 18 years, in order of the date and time of their next regular clinic appointment, selecting the first 25-50% (rounded up to the nearest whole number) of patients. Informed consent, where needed, was sought at the next follow-up session, and the survey form was completed with respect to the last regular clinic appointment prior to the list date. In countries where informed consent was not required, the last 25-50% of the future appointment list could be selected because these would be the patients who had attended the clinic most recently.
Data collection
Patients were enrolled throughout 2003, with the majority enrolled between March and May 2003. A concise, threepage, case report form, designed specifically for each country, was used for recording individual patient data. The case report form focused on: (i) patient age and sex; (ii) aetiology of renal failure; (iii) concomitant pathologies; (iv) type of renal replacement therapy; (v) biological data [haemoglobin concentration, haematocrit, percentage of hypochromic red cells, reticulocytes, C-reactive protein, aluminium, serum ferritin, transferrin saturation (TSAT), serum albumin, immunoreactive parathyroid hormone and urea pre-/post-dialysis); (vi) epoetin therapy (dose, route and frequency of administration); (vii) blood transfusions; (viii) iron and vitamin supplementation; (ix) concomitant therapies; and (x) recent clinical events (within the last 3 months).
Centre data were collected on a three-page questionnaire that focused on policies for starting and adjusting epoetin doses and on managing iron status in both haemodialysis and peritoneal dialysis patients.
All forms were independently double entered into the database and all laboratory values converted to standard units. For the principal laboratory values (haemoglobin, haematocrit, TSAT and serum ferritin), any values outside acceptable limits after conversion were queried and re-entered if necessary. Error checks were made for all values <12.0% or 60% for reported haematocrit values, <4.0 g/dl or 17.0 g/dl for reported haemoglobin concentrations, <20 ng/ml or 3000 ng/ml for reported serum ferritin concentrations, and <5% or 60% for TSAT. Any values that remained as outliers were excluded from further analysis.
Data analysis
When each country's database had been locked, it was downloaded into SPSS (Statistical Package for Social Sciences) for Windows v11.5 for statistical analysis. Most analyses were carried out by the participating country and included summaries of all the parameters/variables included in the survey form. Emphasis was placed on summary analyses demonstrating compliance with the EBPG [2] for haemoglobin and iron status by country and the use of epoetin therapy. When appropriate, separate analyses were produced for each mode of dialysis.
Body weight, sex, age, iron status, aetiology of disease, concomitant pathologies and current/recent clinical events were analysed to determine their effect on haemoglobin levels and epoetin doses in the dialysis population surveyed. For this analysis, the survey data were divided into two country groups. Group 1 (Austria, Belgium, Finland, Israel, Sweden and Switzerland; 2173 patients) had >70% of iii4 C. Jacobs et al.
survey patients with a haemoglobin concentration of 11.0 g/dl, while group 2 (Germany, The Netherlands, Slovenia and the UK; 5068 patients) had only 60-70% of survey patients with a haemoglobin concentration of 11.0 g/dl. Two countries (Poland and Greece; 859 patients) had <60% of survey patients with a haemoglobin concentration of 11.0 g/dl and were not included in the above groupings.
In order to assess any changes in the management of anaemia that may have occurred since the introduction of the EBPG [2] 4 years previously, the findings of ESAM 2003 were compared with those of ESAM 1998 [1] with respect to age, haemoglobin concentration, dose of epoetin and iron status. Only limited comparisons were valid within individual countries because of the differences in sampling fractions and randomization procedures between surveys. More detailed comparisons were possible for Germany, which had the largest sample in both surveys (4384 patients in ESAM 1998 and 3833 patients in ESAM 2003), and, for included patients, the findings were compared for haemoglobin concentration by aetiology of chronic kidney disease, concomitant pathologies, distribution of haemoglobin concentrations, distribution of epoetin doses and the relationship of epoetin dose to the resulting haemoglobin concentration. To account for differences in data obtained from ESAM 1998 and ESAM 2003, only data obtained from the first month observations in ESAM 1998 were used for comparison.
Continuous variables were tabulated using both summary statistics (mean, median and SD) and grouped data, leaving out any values that were either missing or invalid. Parametric variables were compared using two-sample ttests. Non-parametric tests included the Pearson 2 test with continuity correction where appropriate and, where the categories were considered to be ordered, the MantelHaenszel test for linear association. In order to explore the relationships between epoetin doses and haemoglobin values, multiple regression lines were fitted to all the appropriate individual datum points using the epoetin dose as the dependent variable and a function of haemoglobin as the independent variable(s). Fitted regression lines were either linear, of the form y ¼ a þ bx (where y ¼ epoetin dose, x ¼ haemoglobin value, and a and b are constants), or quadratic, of the form y ¼ a þ bx þ cx 2 (where y ¼ epoetin dose, x ¼ haemoglobin value, and a, b and c are constants).
Results
Demographics and epidemiology
A total of 8100 patients from 284 centres were included in the survey (Table 1) . The sample sizes varied from country to country and so do not represent the whole of Europe. It should be noted, in particular, that nearly half of the sample came from one country (Germany). Considerable care was taken in the sampling methodology to sample all types of renal replacement therapy for each centre in proportion to the total numbers attending each centre for any type of renal replacement therapy. The patients in the survey appear to be broadly representative of the general dialysis population [1, 3, 4] in terms of age, sex, body weight and primary cause of renal failure ( Table 2) . The most common cause of end-stage renal failure was diabetic nephropathy, closely followed by chronic glomerulonephritis. Mean (±SD) systolic blood pressure for the overall group was 139.5±23.2 mmHg (median, 140.0 mmHg; range, 60.0-241.0 mmHg), while mean (±SD) diastolic blood pressure was 76.7±12.5 mmHg (median, 80.0 mmHg; range, 18.0-148.0 mmHg). Hypertension was the most common concomitant pathology, followed by ischaemic heart disease, type 2 diabetes and peripheral vascular disease (Table 3) .
Overall, the majority of patients were treated by haemodialysis (Table 2) , with only 10% receiving peritoneal dialysis, similar to the general dialysis population in Europe [5] . The type of renal replacement varied considerably between countries; hence, many of the analyses concern only haemodialysis, haemodiafiltration and haemofiltration patients. The mean duration of renal replacement therapy was shorter for current peritoneal dialysis patients (3 years) than for current haemodialysis patients (just under 4 years) (Table 4) , while the mean overall duration of renal replacement therapy up to the time of the survey was 4 years. The maximum recorded duration of renal replacement therapy was 410 months (34.2 years). Of 7830 patients evaluated, the overwhelming majority had been receiving epoetin for >6 months, though nearly 10% had not received any epoetin (Table 5) .
Haemoglobin concentrations
The overall mean (±SD) haemoglobin concentration for 8055 survey participants was 11.5±1.4 g/dl (median, 11.5 g/dl; range, 4.8-16.8 g/dl). Of these, 66.1% had a haemoglobin concentration of 11.0 g/dl and 36.7% had a haemoglobin concentration of 12.0 g/dl; however, 13.2% had a haemoglobin concentration of <10.0 g/dl. There was a wide variation between countries in the proportion of patients who had a haemoglobin concentration of 11.0 g/dl ( Figure 1 ; Table 6 ). When all patients were included, only three countries achieved this haemoglobin level in >75% of patients (Switzerland, Sweden and Belgium), while two countries (Greece and Poland) achieved it in <65% of patients. This was despite the fact that 74% of centres had an agreed anaemia protocol and almost all centres (96.5%) stated that their target haemoglobin concentration was 11.0 g/dl. When only patients who had received i.v. epoetin-a/b for at least 3 months were included, Germany, The Netherlands and the UK also failed to achieve a haemoglobin concentration 11.0 g/dl in 65% of their patients (Table 7) . In patients receiving epoetin therapy for 3 months, haemoglobin concentrations, overall, were significantly higher in peritoneal dialysis patients than in haemodialysis (including haemofiltration and haemodiafiltration) patients (Table 8) . Overall, 65.7% of patients receiving epoetin therapy for 3 months had a haemoglobin concentration 11.0 g/dl. There were wide variations in haemoglobin response rate (the proportion of patients with a haemoglobin concentration 11.0 g/dl) between countries, particularly in the proportions of patients on extracorporeal renal replacement (haemodialysis, haemofiltration and haemodiafiltration), when assessing patients who had received at least 3 months of epoetin therapy (Table 9 ). In two countries (Austria and Switzerland), the haemoglobin response rate of patients on peritoneal dialysis was lower than that of patients on extracorporeal renal replacement therapy, in contrast to all the other participating countries. The number of peritoneal dialysis patients was very small in some countries, and no statistical tests were carried out for individual countries.
Iron status
Out of 8100 patients, information on iron status was available for 7351 (91%). The mean (±SD) regularly monitored. The haemoglobin response rate was 5-10% higher in patients who had adequate iron status than in those who had functional or absolute iron deficiency.
Route of epoetin administration
Out of 8100 patients, 77.5% received epoetin i.v. Not surprisingly, however, there were large differences between the peritoneal dialysis population (in which only 1% of patients received i.v. epoetin) and the haemodialysis (84.3%), haemofiltration (84.6%) and haemodiafiltration (89.7%) populations. The proportions were similar among patients who had received epoetin for 3 months (Table 11 ). The haemoglobin response rate did not differ by route of administration for patients receiving haemodialysis, haemofiltration and haemodiafiltration (Table 12) .
Dose of epoetin
Because the peritoneal dialysis patients were treated almost exclusively by the subcutaneous (s.c.) route, they were excluded from any analyses of epoetin dose.
There was considerable variation in the mean epoetin dose between countries, with the highest mean dose given in Belgium, Sweden and Israel and the lowest in Poland (Tables 6 and 7) . In all countries, epoetin doses received by patients who did not achieve a haemoglobin concentration of 11.0 g/dl were higher than for patients who did achieve this haemoglobin concentration (Tables 6 and 7) . In individual countries, the doses of i.v. and s.c. epoetin were generally quite similar, with the exception of The Netherlands, where epoetin was given exclusively i.v. In haemodialysis, haemofiltration and haemodiafiltration patients who had received 3 months of epoetin therapy and who had haemoglobin concentrations <11.0 g/dl, the dose of epoetin was 11.8% greater for i.v. administration than for s.c. administration (P ¼ 0.016) ( Table 13 ).
In patients whose haemoglobin concentrations were 11.0 g/dl, however, epoetin doses were 2.5% lower for i.v. than s.c. administration (non-significant).
Multiple regression analysis using all individual datum points indicated that the i.v. epoetin doses varied relatively little from the s.c. doses for patients with haemoglobin values of 11.0 g/dl, but substantially higher i.v. doses than s.c. doses were given in patients who had haemoglobin concentrations <11.0 g/dl ( Figure 2 ). When the mean weekly doses of different types of epoetin were subjected to multiple regression analysis of all the individual datum points, the resultant curves for epoetin-a/b and darbepoetin-a were virtually convergent at a dose ratio of 1 mg darbepoetin-a to 176 IU of epoetin-a/b (95% CI, 1:165-1:187) (Figure 3 ).
Factors affecting epoetin doses and resulting haemoglobin levels
In order to identify the factors that may affect epoetin doses and haemoglobin levels, the countries participating in ESAM 2003 were divided into two groups on the basis of the proportion of patients who had a haemoglobin concentration of 11.0 g/dl (country group 1, >70% of patients; country group 2, 60-70% of patients; Greece and Poland analysed separately). Epoetin doses tended to be higher in group 1, with 49.4% receiving doses of 9000 IU/week compared with 30.8% in group 2 (Table 14) . A weekly epoetin dose ranging from 6000 to 8999 IU was delivered to the greatest proportion of patients in both groups 1 and 2 (21.0 and 28.4%, respectively), and also, quite surprisingly, in Greece (27.1%), in contrast to the low percentage of patients in this country with haemoglobin levels 11.0 g/dl (55.6%, Table 7 ). In Poland, the greatest proportion of patients (27.0%) received weekly epoetin doses of 3000-5999 IU, 20% received no epoetin, and 71.6% received doses below 9000 IU. Overall, patients with epoetin doses of 12 000 IU/week accounted for 25.3% of the population and 53.5% of the total epoetin delivered.
The relationship between haemoglobin concentration and epoetin dose was not linear, and differences in epoetin doses were not constant for all haemoglobin concentrations. In general, patients with lower haemoglobin concentrations tended to receive higher epoetin doses, possibly because the dose had been increased in order to try and raise their haemoglobin concentration. Epoetin doses tended to vary less for patients with haemoglobin concentrations 11.0 g/dl. For all haemoglobin concentrations, the mean epoetin doses were markedly greater for patients in country group 1 than group 2 ( Figure 4 ). The slope of the curve was also steeper in group 1 than in group 2, possibly indicating more efficient use of epoetin ( Figure 4) . Once in the post-titration phase of therapy, epoetin doses were not found to be in direct proportion to body weight. Overall, the mean adjustment for body weight, after standardization for haemoglobin levels, was 16 IU/week/kg body weight (P<0.001). There was, however, substantial variation between countries. In the UK, the mean adjustment for body weight was 77 IU/week/kg body weight (P ¼ 0.002).
There were significant differences between the country groups with respect to age, with group 1 having an older population compared with group 2 (Table 15) . Age, however, appeared to have little effect on either the haemoglobin concentration or the epoetin dose ( Figure 5 , Table 15 ). In group 1, none of the differences in the haemoglobin response rate or epoetin doses (after adjustment for haemoglobin concentration) were significant. In group 2, the haemoglobin response rate was lower than average in patients aged 70-79 years; the mean epoetin dose was also below average in this age group.
The proportion of men and women was very similar in all the 12 participating countries, and in the two country groups. Women generally had a slightly lower mean haemoglobin concentration (11.34 g/dl compared with 11.40 g/dl, respectively) and haemoglobin response rate than men, but there was no evidence of any differences in epoetin doses after adjustment for haemoglobin levels (Table 16) .
The results for iron status are shown in Table 17 . In group 2, 20.3% of patients had a serum ferritin 100 ng/ml, but no values for either TSAT or hypochromic red cells, compared with only 10.8% in country group 1 (P<0.001). There were correspondingly greater proportions of patients in country group 1 compared with 2 for all the other iron status categories. Patients with adequate iron status had above average haemoglobin response rates in both country groups (P<0.01). Patients with functional iron deficiency had below average haemoglobin response rates in both country groups (P<0.01 and P<0.001 for groups 1 and 2, respectively), despite the fact that the mean epoetin doses (after adjustment for haemoglobin concentration) were greater than average (P<0.001 for both groups). There was a general tendency for lower haemoglobin response rates and lower mean epoetin doses for patients with missing values for serum ferritin. The percentage of patients with absolute iron deficiency was similar in groups 1 and 2. For these patients, the average haemoglobin response rate did not differ significantly from that recorded in the total patients in each country group, but a significantly higher mean dose of epoetin was delivered for patients in group 1. For all iron status categories, the mean epoetin doses and haemoglobin response rates were greater in group 1 than in group 2.
The proportions of patients with serum ferritin concentrations of 200-499 and 500 ng/ml were significantly different between the two country groups, with a larger proportion of patients having serum ferritin concentrations of 500 ng/ml and a smaller proportion having serum ferritin concentrations of 200-499 ng/ml in group 2 (Table 18 ). In group 1, there were no significant differences in the haemoglobin response rates for the different serum ferritin categories, although mean epoetin doses were higher for patients with serum ferritin concentrations <200 ng/ml. In group 2, there was no clear pattern regarding serum ferritin concentration, with the differences in mean epoetin doses and haemoglobin response rates between serum ferritin concentrations being reasonably small. In both groups, patients with missing/invalid serum ferritin measurements had significantly lower mean epoetin doses and lower haemoglobin response rates (Table 18) , perhaps indicating generally poor monitoring of these patients. For all serum ferritin categories, the mean epoetin doses and haemoglobin response rates were greater in group 1. There were significantly fewer missing/invalid TSAT values and more TSAT values 20% in group 1 than 2 (Table 19 ). In both country groups, patients with TSAT values <20% received significantly greater mean epoetin doses and showed significantly lower haemoglobin response rates, while the converse was true for patients with TSAT values 20%.
A considerably greater proportion of patients had a serum albumin concentration <40 g/l in group 1 than 2 (Table 20) , which is partly attributable to the a Adequate iron status was defined as serum ferritin 100 ng/ml, transferrin saturation (TSAT) 20% or hypochromic red cells 10%. Functional deficiency was defined as serum ferritin 100 ng/ml, TSAT <20% or hypochromic red cells >10%. Absolute deficiency was defined as serum ferritin <100 ng/ml. Missing refers to serum ferritin 100 ng/ml but TSAT and hypochromic red cells missing.
b 2 test applied for differences in iron status between country groups. c 2 test for differences in percentages of patients with haemoglobin concentration 11.0 g/dl.
d Epoetin doses were compared using regression analysis (adjusting for haemoglobin concentration) between iron status categories within each country group. *P<0.05; **P<0.01; ***P<0.001. lower proportion of missing/invalid values in group 1, partly attributable to the low numbers of patients with serum albumin 40 g/l in Finland and Slovenia (14.3 and 7.7%, respectively), and also partly attributable to the more elderly population in group 1, as serum albumin appears to be inversely correlated with age. The greatest proportion of patients in each country in group 1 had serum albumin levels in the range 30.0-39.9 g/l, indicating suboptimal nutrition rather than severe malnutrition (data not shown). In both country groups, patients with serum albumin concentrations <40 g/l responded less well to epoetin therapy than those patients with serum albumin concentrations 40 g/l. For most patients, only the principal aetiology of chronic kidney disease was recorded, though in a small number of cases multiple aetiologies were recorded. In group 2, a significantly greater proportion of patients had chronic glomerulonephritis and a significantly lower proportion of patients had renal vascular disease as the underlying cause of chronic kidney disease compared with group 1 (Table 21) . The haemoglobin response rates were slightly, but significantly, lower in patients with diabetic nephropathy than other aetiologies in group 2, but otherwise there were no significant differences between haemoglobin response rates within each country group. For all aetiologies, however, the haemoglobin response rate was always greater in group 1 than 2. In both country groups, patients with multiple myeloma received greater mean epoetin doses (after adjustment for haemoglobin levels) than other aetiologies (Table 21 ). Haemoglobin response rates were also lower for multiple myeloma patients, though this was not significant (possibly due to small numbers).
All the concomitant pathologies recorded in ESAM 2003 are given in Table 22 . A significantly greater proportion of patients in group 2 compared with group 1 were recorded as having hypertension and type 2 diabetes. Haemoglobin response rates were generally greater in group 1 than 2, the only exceptions being type 1 diabetes and recent allograft rejection. Patients in group 1 also received greater mean epoetin doses for all concomitant pathologies than group 2. In group 2, patients with chronic infection/inflammation had a substantially lower than average haemoglobin response rate compared with all other concomitant pathologies, despite the fact that they received a significantly greater mean epoetin dose (after adjustment for haemoglobin levels). Although there were similar trends for patients with chronic infection/ inflammation in group 1, this was not significant (possibly due to small numbers). As might be expected from the increased prevalence of hypertension in group 2 compared with group 1, a greater proportion of patients in group 2 also received antihypertensive drugs (Table 23) . Patients receiving steroids and other immunosuppressives, of which there were small numbers, appear to respond less well to epoetin therapy than patients receiving other concomitant therapies. Patients in group 1 received greater mean epoetin doses and had higher haemoglobin response rates than patients in group 2, irrespective of the concomitant drugs they received. Recent clinical events recorded for the survey patients are summarized in Table 24 . Due to the very small numbers of individually coded recent malignant diseases, cardiovascular complications and surgery, the data were analysed for these disease groups as a whole. There was a tendency for a greater proportion of patients in group 1 than in group 2 to have experienced a recent clinical event. There was also a general tendency, in both country groups, for patients with any type of recent clinical event to have received higher mean epoetin doses and show lower haemoglobin response rates compared with patients without recent clinical events. However, for all types of recent clinical event patients, patients in group 1 showed greater haemoglobin response rates and had received higher mean epoetin doses than group 2.
Comparison between ESAM 1998 and ESAM 2003
In general, the patient population in ESAM 2003 was older than in ESAM 1998. In ESAM 2003, the proportion of patients aged 70 years was greater in every country except The Netherlands, although this was not always statistically significant ( Figure 6 ). For ESAM 2003, mean haemoglobin levels were higher in all but two of the eight countries compared with ESAM 1998 ( Figure 7) ; for most countries, the difference was significant (P<0.05). In The Netherlands, the proportion of patients with a haemoglobin concentration of 11.0 g/dl was slightly lower (but not significantly), while in Sweden it remained almost unchanged. In ESAM 2003, the mean weekly epoetin-a/b doses were higher in all of the eight countries, and this increase was significant (P<0.05) for all of the countries except Austria and Sweden (Figure 8) .
Overall, both the reporting of iron status and iron status itself improved between ESAM 1998 and ESAM 2003. The proportion of patients for whom both serum ferritin concentration and TSAT values were reported was higher in every country except Greece and Sweden ( Figure 9 ). Reporting in Greece fell below 20%.
Similarly, in ESAM 2003, the proportion of patients with adequate iron status (defined as a serum ferritin concentration of 100 mg/ml and a TSAT value of 20%; hypochromic red cells were not included in the definition for comparability between the two surveys) was significantly higher (P<0.03) in all countries except Switzerland (non-significant increase) and for Greece and Sweden (the countries in which reporting was poorer), in which the proportion fell (P<0.001) (Figure 10 ).
Comparison between ESAM 1998 and ESAM 2003: Germany only
In Germany, the mean age of the patients was 61.2 years (with 32% 70 years) in ESAM 1998 and 63.2 years (with 38% 70 years) in ESAM 2003.
The haemoglobin response rate was higher for all the aetiologies of chronic kidney disease (Figure 11 
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Patients, n (%) for all but multiple myeloma). Similarly, in ESAM 2003, a higher proportion of patients with a haemoglobin concentration of 11.0 g/dl was recorded for all the different concomitant pathologies (Figure 12 ), though the magnitude of the increase varied between pathologies (P<0.05 for all but neoplasia and haemoglobinopathy). Over 70% of patients with hepatitis or type 1 diabetes had a haemoglobin concentration of 11.0 g/dl in ESAM 2003, which was substantially higher compared with ESAM 1998, whereas <50% of patients with neoplasia, haemoglobinopathy and chronic infection had a haemoglobin concentration of 11.0 g/dl in ESAM 2003, despite the percentage being greater than in ESAM 1998. ESAM 1998 889  831  291  470  198  65  17  625  ESAM 2003 629  729  296  298  181  34  21  440 Haemoglobin response rate (%) P < 0.001 P < 0.001 P < 0.001 P < 0.001 P = 0.004 
Discussion
The objectives for conducting ESAM 2003 were to assess any changes that might have occurred in the management of dialysis patients in the 4 years that have elapsed since the first survey (ESAM 1998) and to determine whether any such changes could be associated with significant improvements in the outcomes observed in these patients.
ESAM 1998 [1] was conducted in parallel with the introduction of the EBPG [2] and revealed that much progress was needed to meet the objectives set by the guidelines for the treatment of anaemia in dialysis patients. ESAM 2003 varied substantially from ESAM 1998, particularly with respect to the countries involved and the sampling and randomization processes. In addition, ESAM 1998 was a prospective survey in which data were obtained over a period of 6 months, whereas ESAM 2003 was a 1 day retrospective spot survey. Although the differences between surveys precluded detailed comparisons of the data, limited comparisons within the eight individual countries that participated in both surveys are considered valid, allowing an assessment of the changes in anaemia management in dialysis patients over the last 4 years. Significant improvements in haemoglobin response rates (the percentage of patients achieving haemoglobin levels 11.0 g/dl) were observed in six of the eight countries. Wide variation was observed between countries in both surveys with regard to haemoglobin response rates; these ranged from 55.5 to 80.5% in ESAM 2003, which was an improvement over those observed in ESAM 1998 (45.3-74.7%) [1] . The most probable cause for the improvement in anaemia management over the last 4 years appears to be an increase in epoetin dose. Mean epoetin doses increased between ESAM 1998 and ESAM 2003 in all eight countries, and these increases were statistically significant in six countries. In addition, the more detailed comparison performed for Germany revealed that the large improvement in haemoglobin response rates between ESAM 1998 and ESAM 2003 (18.2% increase) was associated with increases in epoetin doses In order to manage renal anaemia efficiently, it is important to understand the relationship between epoetin dose and haemoglobin level. We explored this relationship in detail and found that for i.v. epoetin administration, the best fit was a quadratic function, indicating that mean epoetin doses vary only slightly as haemoglobin values increase above 11.0 g/dl, but rise substantially as haemoglobin values decrease below 11.0 g/dl. For s.c. epoetin administration, the relationship between epoetin doses and haemoglobin levels was not as well defined due to the smaller numbers in the sample. The quadratic relationship was not statistically significant and mean epoetin doses did not appear to rise as haemoglobin values fell. The difference between mean i.v. and s.c. doses was minimal for haemoglobin values >11.0 g/dl, but i.v. doses were substantially higher for low haemoglobin values. These data suggest that there would be little or no difference in mean epoetin-a/b doses between the two routes of administration in countries (and indeed individual centres) where patients, as a group, are maintained at high haemoglobin levels, whereas the differences would be fairly substantial in countries where overall haemoglobin levels are low. It should be noted that there was considerable variation in the slope of the i.v. epoetin dose vs haemoglobin concentration curve between countries, and the steeper curves appear to be indicative of more efficient use of epoetin.
Comparisons were made between i.v. doses of epoetin-a/b and darbepoetin. Haemoglobin response rates were comparable between the two subsets. Fitting parallel quadratic regression lines to the two sets of data revealed that the best estimate of the overall dose ratio of darbepoetin (mg) to epoetin-a/b (IU) was 1:176 with 95% CIs of 1:165-1:187. This ratio is well below that found in other studies [6, 7] and could possibly be criticized because we do not know if or when patients were switched between types of erythropoiesis-stimulating agents. However, other published comparisons could equally be criticized for only switching in one direction (from epoetin-a/b to darbepoetin) and for having a primary end-point aimed to assess differences between the respective frequencies of administration of the two compounds [8, 9] . From ESAM 2003, we do at least know that, at some point in time, the two groups were very comparable with regard to haemoglobin levels.
In order to identify the effect of factors recorded in ESAM 2003 on the response to epoetin therapy, the countries were divided into two groups based on the haemoglobin response rates within the countries. Group 1 and group 2 consisted of countries with haemoglobin response rates >70 and 60-70%, respectively. The most significant difference between the two groups of countries was in the mean epoetin doses given, which were substantially higher in group 1 for all haemoglobin values and for all factors analysed. Patients in group 1 had lower haemoglobin response rates than those in group 2 in relation to only two factors, namely type 1 diabetes and recent allograft rejection as a concomitant pathology. In both cases, the lower haemoglobin response rates in group 1 could possibly be attributed to low numbers of patients.
Even if too low an epoetin dose is indeed a major risk factor for not achieving satisfactory haemoglobin levels, other causes may also have a role, as exemplified by the high percentage of patients in Greece with a haemoglobin level <11.0 g/dl despite quite a high mean dose of epoetin. One other crucial factor for achieving a satisfactory response to epoetin therapy is adequate iron status. Patients in both country groups with adequate iron status had greater haemoglobin response rates with lower mean epoetin doses, while patients with functional iron deficiency had lower than average haemoglobin response rates despite receiving higher epoetin doses. This may be the main factor affecting haemoglobin response in Greece, as serum ferritin and TSAT values were reported in <20% of patients, and <10% had adequate iron status. As already reported in ESAM 1998, and quite surprisingly, functional iron deficiency had a stronger negative impact on haemoglobin response rates than absolute iron deficiency [1] . Serum albumin concentration also appears to be quite important, as patients with suboptimal serum albumin concentrations (<40 g/l) had lower haemoglobin response rates despite receiving higher epoetin doses in both groups, although differences in epoetin doses were only significant in group 1. In addition, patients with recent infections treated with antibiotics or those with acute inflammation generally responded poorly to epoetin therapy. It is interesting to note that group 1 had a more elderly patient population and, although no significant association between age and response to epoetin therapy was detected, patients in this group tended to have experienced more recent clinical events and have lower serum albumin concentrations than those in group 2.
The aetiology of chronic kidney disease and concomitant pathologies appears to have a somewhat lesser effect on epoetin response. Patients with multiple myeloma received higher epoetin doses in both groups, and patients with diabetic nephropathy received lower epoetin doses in group 2, though these differences were relatively small in magnitude. Patients in group 2 with active neoplasia or chronic infection/inflammation had lower haemoglobin response rates and higher epoetin doses. The same profile was observed in group 1 but was not significant, possibly due to the low numbers of patients with these concomitant pathologies. Patients in group 2 with type 2 diabetes and congestive heart failure had lower haemoglobin response rates, while iii22 C. Jacobs et al.
those with hepatitis had higher haemoglobin response rates with approximately the same dose of epoetin compared with other concomitant pathologies. Patients in country group 2 who were treated with angiotensin II receptor inhibitors had a lesser response to epoetin (higher epoetin doses and lower haemoglobin response rates), which was not the case for those in both groups receiving angiotensin-converting enzyme (ACE) inhibitors (see Table 23 ). Patients in country group 2 treated with steroids and/or immunosuppressive drugs had a lower response to epoetin compared with other medications; these medications are usually administered to patients with a systemic disease or a transplanted organ.
Although the randomization and sampling processes in ESAM 2003 were carefully designed to obtain samples from each country that were representative of the country as a whole, there was variation between countries, so caution has to be exercised when modelling factors that might affect both haemoglobin levels and epoetin doses. This analysis is limited by the fact that the data were generated from a 1 day spot survey. There is, indeed, a fundamental problem in analysing a spot survey to ascertain the influence of various factors on both haemoglobin levels and epoetin doses, because factors such as concomitant pathologies and recent clinical events tend to affect haemoglobin levels, which result in changes in epoetin doses. Finally, we have only examined the impact of the limited list of factors recorded in ESAM 2003 and recognize that there are certainly other parameters that were not measured in the survey, such as economic factors which could be equally, if not more, important in determining the modalities, dosages and extent of epoetin administration and the consequent haemoglobin levels.
Despite wide differences in study design, the results of the ESAM 2003 survey may, to some extent, be compared with the recently published reports of the Dialysis Outcomes and Practice Patterns Study (DOPPS) [10] . DOPPS was a prospective study in which data were collected at baseline and every subsequent 4 months. It involved 11 041 haemodialysis patients randomly selected from 309 dialysis facilities in 12 countries. However, only four countries (Belgium, Germany, Sweden and the UK) were included in both the DOPPS and ESAM 2003 survey. Although mean haemoglobin response rates and epoetin doses were reported for patients receiving epoetin-a/b for >180 days in DOPPS compared with >3 months in ESAM 2003, similar outcomes were reported in both surveys. If DOPPS figures for patients on dialysis for >180 days excluding darbepoetin are compared with ESAM 2003 figures for patients on epoetin-a/b therapy for at least 6 months, the mean weekly epoetin dose and haemoglobin response rates for Germany are 6846 IU and 65% in DOPPS vs 7140 IU and 66% in ESAM 2003, respectively. In general, both mean epoetin doses and haemoglobin response rates were slightly higher in ESAM 2003, which could partially be attributed to the fact that this survey was conducted after the DOPPS (2003-2004 compared with 2002-2003) .
Despite the differences in design and methodology, the two surveys thus concur on several important outcomes.
(i) There have been significant improvements in anaemia management in the last 4 years, yet many patients remain below the target level set in the current guidelines for the management of anaemia in dialysis patients [11] . (ii) There is considerable variation in haemoglobin response rates between countries, and countries with the highest haemoglobin response rates have the highest mean epoetin doses, whereas countries with the lowest haemoglobin response rate have the lowest mean epoetin doses. (iii) Adequate iron status is associated with better haemoglobin response rates. (iv) Patients with the lowest haemoglobin levels receive the highest doses of epoetin. (v) In both studies, just over 8% of the population studied received mean epoetin doses 18 000 IU/ week [10] .
There is one area in which the findings of different surveys notably vary-dose differences between i.v. and s.c. administration of epoetin. DOPPS reported a reduction in epoetin dose of 14% with s.c. administration, though a difference of only 3% was reported in the USA [8] . We report here that the difference between i.v. and s.c. doses of epoetin are only significant for haemoglobin values <11 g/dl, and the lower the haemoglobin value the greater the difference between i.v. and s.c. doses. Fitting parallel linear regression lines to the data for i.v. and s.c. administration of epoetin, as appears to have been done in DOPPS [10] , could mask these differences over ranges of haemoglobin values. Based on our data, we suggest that there would be substantial differences in mean epoetin doses between the two routes of administration in countries where overall haemoglobin levels are low and minimal differences in countries where patients, as a group, are maintained at high haemoglobin levels. This is, in fact, what is reported in DOPPS, in which patients in the USA received high mean epoetin doses, had higher haemoglobin levels and showed a small difference between s.c. and i.v. administered epoetin doses [10] .
Conclusions
The general conclusion from this survey is that, although anaemia management has improved in patients with chronic kidney disease over the last 5 years, many patients still have haemoglobin levels below the current recommendations. There are significant differences in anaemia management between countries, and the most probable causes for better management in countries with haemoglobin response rates >70% appear to be the administration of higher epoetin doses and better monitoring and management of iron status. These results suggest that significant improvements in anaemia management can be made through measures that are part of good medical practice [12, 13] . These include optimal iron supplementation and iron status monitoring [14] [15] [16] [17] , which have to be carefully adjusted for each individual patient; and identifying overt or covert causes of inflammation [18, 19] , malnutrition [20] , inadequate dialysis [21] [22] [23] and other documented causes of 'resistance to epoetin therapy' [11, 12] . Real obstacles to achieving adequate management of anaemia in dialysis patients with epoetin therapy exist for only a very limited number of categories of patients, such as those with active neoplasia, myeloma or any disease requiring treatment including immunosuppressive drugs, such as systemic diseases (e.g. systemic lupus erythematosus and Wegener's disease) or allograft rejection.
